CN Patent

CN119174751A — 用于治疗焦虑相关病症的组合物和方法

Assigned to Hoffman Technology Co ltd · Expires 2024-12-24 · 1y expired

What this patent protects

本申请涉及用于治疗焦虑相关病症的组合物和方法。本发明提供了用于在有此需要的对象中治疗焦虑相关病症(包括OCD和SAD)以及用于在有此需要的对象中减轻焦虑、强迫观念行为或强迫行为的方法、组合物和药盒。

USPTO Abstract

本申请涉及用于治疗焦虑相关病症的组合物和方法。本发明提供了用于在有此需要的对象中治疗焦虑相关病症(包括OCD和SAD)以及用于在有此需要的对象中减轻焦虑、强迫观念行为或强迫行为的方法、组合物和药盒。

Drugs covered by this patent

esketamine-hydrochloride (ESKETAMINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN119174751A
Jurisdiction: CN
Classification: —
Expires: 2024-12-24
Drug substance claim: No
Drug product claim: No
Assignee: Hoffman Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.